Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum is a pharmaceutical drug with 21 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
8
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
94.1%
16 of 17 finished
5.9%
1 ended early
3
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease
Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease
Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
Clinical Trials (21)
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease
Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease
Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules
A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy
A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture
Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder
Retreatment of Recurrent Dupuytren's Contractures
Collagenase Option for Reduction of Dupuytren's Contracture in Japan
Short-term Function and Pain After Treatment for Dupuytren's Disease
A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 21